Bavituximab Biosimilar – Anti-Phosphatidylserine mAb – Research Grade from ProteoGenix; catalogue PX-TA1107; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Bavituximab Biosimilar is a monoclonal antibody (mAb) that targets phosphatidylserine (PS), a phospholipid that is normally located on the inner leaflet of the cell membrane. However, in certain disease states, such as cancer and viral infections, PS becomes exposed on the outer leaflet of the cell membrane. This exposure of PS is associated with various pathological processes, making it an attractive therapeutic target. Bavituximab Biosimilar is a research grade version of the original Bavituximab, which has shown promising results in clinical trials and is currently being developed as a potential treatment for various diseases.
Bavituximab Biosimilar is a recombinant, humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to PS, while the constant region determines the antibody’s effector functions. Bavituximab Biosimilar is produced using Chinese hamster ovary (CHO) cells, which have been genetically modified to produce the antibody. This ensures consistent and high-quality production of the antibody.
Bavituximab Biosimilar binds to PS with high specificity and affinity, leading to the formation of immune complexes. These immune complexes activate the body’s immune system, specifically the complement system, which is responsible for eliminating foreign invaders and damaged cells. Bavituximab Biosimilar also activates natural killer (NK) cells, which are a type of white blood cell that can directly kill cancer cells and virus-infected cells. Furthermore, Bavituximab Biosimilar has been shown to inhibit the growth of new blood vessels, a process known as angiogenesis, which is crucial for the survival and growth of tumors.
Bavituximab Biosimilar has shown promising results in preclinical studies and is being investigated for its potential therapeutic applications in various diseases. One of the most promising applications of Bavituximab Biosimilar is in the treatment of cancer. PS is highly expressed on the surface of cancer cells, making it an attractive target for cancer therapy. Bavituximab Biosimilar has been shown to enhance the body’s immune response against cancer cells, leading to their destruction. It has also been shown to inhibit tumor growth by blocking angiogenesis. Clinical trials are currently underway to evaluate the safety and efficacy of Bavituximab Biosimilar in different types of cancer.
In addition to cancer, Bavituximab Biosimilar is also being investigated as a potential treatment for viral infections. PS is exposed on the surface of virus-infected cells, making them susceptible to Bavituximab Biosimilar-mediated immune clearance. In preclinical studies, Bavituximab Biosimilar has been shown to enhance the body’s immune response against viruses such as HIV, hepatitis C, and influenza. Clinical trials are currently ongoing to evaluate the efficacy of Bavituximab Biosimilar in these viral infections.
In conclusion, Bavituximab Biosimilar is a research grade version of the original Bavituximab, which is a monoclonal antibody that targets phosphatidylserine. It is composed of two heavy chains and two light chains and is produced using genetically modified CHO cells. Bavituximab Biosimilar has shown promising results in preclinical studies and is being investigated for its potential therapeutic applications in cancer and viral infections. Its ability to activate the immune system and inhibit angiogenesis makes it a promising candidate for the treatment of these diseases. Further clinical trials will determine the safety and efficacy of Bavituximab Biosimilar, and if successful, it could potentially become a valuable addition to the current treatment options for these diseases.
ProteoGenix catalogue number PX-TA1107. For research use only.
Target: Bavituximab Biosimilar – Anti-Phosphatidylserine mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Molecular weight: 145kDa; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Bavituximab Biosimilar – Anti-Phosphatidylserine mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
